Q (haiku): list the portal studies for pediatric cancers that were published in the last 5 years

▶ list_studies
{
 "search": "pediatric",
 "limit": "100",
 "verbose": "true"
}

✗ error
<tool_use_error>Error: No such tool available: mcp__navigator__list_studies</tool_use_error>

▶ list_studies
{
 "search": "pediatric",
 "limit": 100,
 "verbose": true
}

◀ result
{"result":[{"cancer_study_identifier":"all_phase2_target_2018_pub","name":"Pediatric Acute Lymphoid Leukemia - Phase II (TARGET, 2018)","description":"Whole genome or whole exome sequencing on 298 Pediatric Acute Lymphoid Leukemia - Phase II samples. Comprehensive profiling of ALL Phase 2 samples. <p>TARGET data is intended exclusively for biomedical research using pediatric data (i.e., the research objectives cannot be accomplished using data from adults) that focus on the development of more effective treatments, diagnostic tests, or prognostic markers for childhood cancers. Moreover, TARGET data can be used for research relevant to the biology, causes, treatment and late complications of treatment of pediatric cancers, but is not intended for the sole purposes of methods and/or tool development (please see <a href=\"https://ocg.cancer.gov/programs/target/using-target-data\">Using TARGET Data</a> section of the OCG website). If you are interested in using TARGET data for publication or other research purposes, you must follow the <a href=\"https://ocg.cancer.gov/programs/target/target-publication-guidelines\">TARGET Publication Guidelines</a>.</p","type_of_cancer_id":"bll","sample_count":1978,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=all_phase2_target_2018_pub"},{"cancer_study_identifier":"nbl_target_2018_pub","name":"Pediatric Neuroblastoma (TARGET, 2018)","description":"Whole genome or whole exome sequencing on 1089 NBL samples. Comprehensive profiling of 1089 NBL samples. <p>TARGET data is intended exclusively for biomedical research using pediatric data (i.e., the research objectives cannot be accomplished using data from adults) that focus on the development of more effective treatments, diagnostic tests, or prognostic markers for childhood cancers. Moreover, TARGET data can be used for research relevant to the biology, causes, treatment and late complications of treatment of pediatric cancers, but is not intended for the sole purposes of methods and/or tool development (please see <a href=\"https://ocg.cancer.gov/programs/target/using-target-data\">Using TARGET Data</a> section of the OCG website). If you are interested in using TARGET data for publication or other research purposes, you must follow the <a href=\"https://ocg.cancer.gov/programs/target/target-publication-guidelines\">TARGET Publication Guidelines</a>.</p>","type_of_cancer_id":"nbl","sample_count":1089,"has_guide":false,"url":"https://www.cbioportal.org/study/summary?id=nbl_target_2018_pub"},{"cancer_study_identifier":"aml_target_2018_pub","name":"Pediatric Acute Myeloid Leukemia (TARGET, 2018)","description":"Whole genome or whole exome sequencing on 333 TARGET-AML samples. Comprehensive profiling of TARGET-AML samples. <p>TARGET data is intended exclusively for biomedical research using pediatric data (i.e., the research objectives cannot be accomplished using data from adults) that focus on the development of more effective treatments, diagnost … (9828 more chars)

═ answer (success)
## Pediatric Cancer Studies (Published 2021–2026)

Here are the **pediatric cancer studies** in cBioPortal **published in the last 5 years** (2021–2026), sorted by publication year:

### **2025**
1. [Pediatric Tumors (MSK, 2025)](https://www.cbioportal.org/study/summary?id=pancan_ped_mai_msk_2025) — 60 samples from the Make An Impact (MAI) program via MSK-IMPACT

### **2024**
2. [Pediatric Acute Myeloid Leukemia (St. Jude, Nat Genet 2024)](https://www.cbioportal.org/study/summary?id=aml_stjude_2024) — 887 pediatric AML cases with RNA-Seq, WES, WGS

### **2023**
3. [Pediatric Neuroblastoma (MSK, Nat Genet 2023)](https://www.cbioportal.org/study/summary?id=nbl_msk_2023) — 223 neuroblastoma tumor/normal pairs via MSK-IMPACT
4. [Pediatric solid tumor PDXs (UTHSA, Nat Commun 2023)](https://www.cbioportal.org/study/summary?id=pancan_pdx_uthsa_2023) — 68 PDXs + 65 patient tumors (136 samples)
5. [Pediatric Rhabdomyosarcomas (MSK, JCO Precis Oncol 2023)](https://www.cbioportal.org/study/summary?id=rms_msk_2023) — 24 rhabdomyosarcoma cases via MSK-IMPACT

### **2022**
6. [Pediatric Pancan Tumors (MSK, Nat Commun 2022)](https://www.cbioportal.org/study/summary?id=mixed_kunga_msk_2022) — 135 pediatric mixed tumors via MSK-IMPACT
7. [Pediatric European MAPPYACTS Trial (Gustave Roussy, Cancer Discov 2022)](https://www.cbioportal.org/study/summary?id=pancan_mappyacts_2022) — 786 pediatric samples with actionable mutations

### **2020–2021**
8. [Pediatric Brain Cancer (CPTAC/CHOP, Cell 2020)](https://www.cbioportal.org/study/summary?id=brain_cptac_2020) — 218 pediatric brain tumors (7 histological types) with proteogenomics
9. [Pediatric Low-Grade Glioma (CTF, Acta Neuropathol 2021)](https://www.cbioportal.org/study/summary?id=lgg_ctf_synodos_2025) — 31 pediatric LGG samples with neurofibromatosis

**Total: 9 studies** published in the last 5 years, spanning pediatric leukemia, solid tumors, brain tumors, and PDX models.